We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.50 | -8.20% | 28.00 | 27.00 | 29.00 | 30.50 | 27.50 | 30.50 | 759,393 | 09:13:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -6.13 | 19.57M |
From Apr 2019 to Apr 2024
TIDMSAR
RNS Number : 6260P
Sareum Holdings PLC
21 November 2016
(AIM: SAR) 21 November 2016
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Notice of AGM
The Company announces that a notice has been sent to its shareholders to convene its Annual General Meeting ("AGM") which is to be held at 10.00 a.m. on 15 December 2016 at the offices of WH Ireland Limited, 24 Martin Lane, London EC4R 0DR.
Further to the announcement of the Company's final results for the year ended 30 June 2016 released on 2 November 2016, the Company announces that the report and accounts have been posted to those shareholders that requested hard copies.
In addition, an e mail has been sent to both shareholders that have opted for electronic communication and beneficial owners of shares with information rights informing them, inter alia, that the report and accounts are now available on the Company's website.
The notice of AGM and the aforementioned e mail are also available on the Company's website www.sareum.com.
For further information:
Sareum Holdings plc Tim Mitchell 01223 497 700 WH Ireland Limited (Nominated Adviser and Co-Broker) Chris Fielding / Nick Prowting 020 7220 1666 Hybridan LLP (Co-Broker) Claire Noyce / William Lynne 020 3764 2341/2342 The Communications Portfolio (Sareum Media enquiries) Ariane Comstive Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL(R) can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAAKFDBOBDDCDD
(END) Dow Jones Newswires
November 21, 2016 02:01 ET (07:01 GMT)
1 Year Sareum Chart |
1 Month Sareum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
